| Literature DB >> 36076921 |
Katarzyna Krukiewicz1,2, Alicja Kazek-Kęsik3,4, Monika Brzychczy-Włoch5, Marek J Łos6, Collins Njie Ateba7, Parvaneh Mehrbod8, Saeid Ghavami9,10,11,12, Divine Yufetar Shyntum4.
Abstract
Biofilms are complex structures formed by bacteria, fungi, or even viruses on biotic and abiotic surfaces, and they can be found in almost any part of the human body. The prevalence of biofilm-associated diseases has increased in recent years, mainly because of the frequent use of indwelling medical devices that create opportunities for clinically important bacteria and fungi to form biofilms either on the device or on the neighboring tissues. As a result of their resistance to antibiotics and host immunity factors, biofilms have been associated with the development or persistence of several clinically important diseases. The inability to completely eradicate biofilms drastically increases the burden of disease on both the patient and the healthcare system. Therefore, it is crucial to develop innovative ways to tackle the growth and development of biofilms. This review focuses on dental- and implant-associated biofilm infections, their prevalence in humans, and potential therapeutic intervention strategies, including the recent advances in pharmacology and biomedical engineering. It lists current strategies used to control the formation of clinically important biofilms, including novel antibiotics and their carriers, antiseptics and disinfectants, small molecule anti-biofilm agents, surface treatment strategies, and nanostructure functionalization, as well as multifunctional coatings particularly suitable for providing antibacterial effects to the surface of implants, to treat either dental- or implant-related bacterial infections.Entities:
Keywords: anti-biofilm agent; antibacterial coating; antibacterial therapy; antimicrobial resistance; bacterial biofilm; bacterial infection; medical device
Mesh:
Substances:
Year: 2022 PMID: 36076921 PMCID: PMC9455909 DOI: 10.3390/ijms23179526
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Schematic representation of the formation and dispersal of bacterial biofilm. Attachment represents the initial phase of biofilm growth, during which planktonic bacteria bind to an abiotic or biotic surface. Thereafter, microcolonies are formed when irreversibly adhered bacteria grow as a multicellular community. Proliferation and secretion of extracellular matrix components leads to the growth and maturation of the biofilm. Finally, detachment and dispersal of biofilms results in the release of both planktonic and microcolonies to the environment.
Figure 2Schematic representation of some clinically important biofilms. Periodontitis and carrier are examples of dental infections resulting from a change in the homeostasis between the host and mouth microbiome, leading to the proliferation of pathogenic bacteria. Implant rejection is a highly undesired endpoint of a bacterial infection from either exogenous or host-associated bacteria.
Figure 3Schematic representation of antibiotic-based strategies for controlling the formation of clinically important biofilms.
Figure 4Schematic representation of anti-biofilm mechanisms of small molecules, including inhibition of biofilm formation by pilicides and curlicides, interfering with c-di-GMP (bis-(3′-5′)-cyclic dimeric guanosine monophosphate) signaling, or inhibition of quorum sensing (QS).
Figure 5Schematic representation of surface treatment strategies to modulate bacteria adhesion and biofilm formation by changing surface properties, namely wettability, roughness, and topography.
Figure 6Schematic representation of surface modification strategies allowing the control of biofilm growth on the surface of implants, namely electroactive surfaces, surfaces engineered by laser treatment, biomimetic anti-adhesion coatings, multifunctional antibacterial coatings, switchable and self-responsive antibacterial coatings, and antibacterial/anti-adhesive porous oxide layers.
Antimicrobial effects of various porous oxide layer coatings formed via plasma electrolytic oxidation on metal surfaces or the effect of hybrid coatings on microbial activity when the base layer is formed by anodization. The cytocompatibility of the coatings is evaluated to determine the balance between the cytotoxicity of various bacteria and the acceptable cytocompatibility of treated surfaces.
| Antibacterial Agent | Type of Coating | Bacterial Strain | Cytocompatibility Analysis | Comments | Ref. |
|---|---|---|---|---|---|
| Cu2O, ZnO | TiO2 with incorporated Cu2O and ZnO | n.a. * | [ | ||
| CuO, Cu3(PO4)2 | TiO2 with incorporated CuO, Cu3(PO4)2 | osteoblast-like MG-63 cells | anti-adhesive properties | [ | |
| Cu2O, CuO | Al2O3 with incorporated Cu2O, CuO | sulfate reducing bacteria | n.a. | anti-biofilm formation properties | [ |
| Ag, Pt | hybrid coating TiO2-Ag or Pt deposited by ion implantation | osteoblast MC3T3-E1 subklon 4 cell | anti-adhesive properties | [ | |
| Ag NPs, Zn NPs, Pt NPs | TiO2 with incorporated selected NPs or mixture of NPs | MC3T3-E1 cells | - | [ | |
| Ag nanoparticles | TiO2 with incorporated Ag nanoparticles | n.a. | - | [ | |
| Ag, Ag2O NPs | TiO2 with incorporated Ag and Ag2O NPs | MC3T3-E1 cells | - | [ | |
| AgNO3 | TiO2 with incorporated Ag compounds | n.a. | - | [ | |
| ZrO2, ZnO | deposition of Zr on Ti surface by pulsed direct current (DC) magnetron sputtering and then anodization | MC3T3-E1 cell | - | [ | |
| ZrO2 | TiO2 with incorporated ZrO2 | n.a. | - | [ | |
| ZnO NPs | TiO2 with incorporated ZnO | n.a. | - | [ | |
| Zn(CH3COO)2 | TiO2 with Zn-based compound and hydrothermal treatment | n.a. | - | [ | |
| Na2WO4 | TiO2 with incorporated W-compounds | n.a. | - | [ | |
| Na2WO4 | TiO2 with incorporated W-compounds | n.a. | - | [ | |
| Al2O3 | anodized Al alloy in H2SO4 solution | n.a. | - | [ | |
| graphene oxide | hybrid coating: TiO2-graphen oxide deposited by EPD | n.a. | anti-adhesive properties | [ | |
| Ta2O5 | hybrid coating TiO2-Ta2O5 deposited by high-power impulse magnetron sputtering | human skin fibroblasts (HSF) and human osteosarcoma cells MG-63 | - | [ | |
| C6H9O6Y | TiO2 with incorporated Y2O3 | fibroblast | - | [ | |
| ZrO2 | MgO with incorporated ZrO2 | n.a. | - | [ | |
| Na2B4O7 | TiO2 with boron-based compounds | Adipose derived stem cells (ADSC) | - | [ |
* n.a.—not analyzed; NPs—nanoparticles.